M. Yoneda

Epidemiology · with Sumida · 2017

A researcher in the Science corpus: 1 paper; trusts 1 researcher and is trusted by 0 researchers here, as inferred from the citation graph.

Subfields

Whom M. Yoneda trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. Z. Younossi

Papers from M. Yoneda's perspective

Ordered by how strongly the researchers M. Yoneda trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Increased risk of mortality by fibrosis stage in non-alcoholic fatty liver disease: Systematic Review and Meta-analysis (Hepatology)
  2. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. (The Lancet)
  3. Magnetic Resonance Imaging More Accurately Classifies Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease Than Transient Elastography. (Gastroenterology)
  4. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: Results of a randomized trial (Hepatology)
  5. Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomes (Hepatology)
  6. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. (Journal of Hepatology)
  7. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe (Hepatology)
  8. Decoding cell death signals in liver inflammation. (Journal of Hepatology)
  9. Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease. (Journal of Hepatology)
  10. Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis. (Journal of Hepatology)

Their papers